UK-based Stabilitech has been recognised by the World Health Organisation (WHO) as a vaccine developer.
Stabilitech board member Dr Drew noted: “The WHO is a pivotal player when it comes to vaccines, it sets all of the guidelines adopted by bio-pharmaceutical companies for vaccines development.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
“Being added to the WHO’s list as a recognised vaccine developer is huge news for us and the UK biopharma sector, providing a level of global recognition that Stabilitech is an active player in finding a vaccine for COVID-19.”
This announcement comes a fortnight after the company announced its intentions to raise $6m in order to join the race to develop a vaccine against Covid-19; Stabilitech’s candidate is an oral vaccine OraPro-COVID-19.
“COVID-19 infects the mucous membranes, or linings, of the ear, nose throat and lungs. That is why we are targeting our vaccine to hit COVID-19 where it sits – in mucosal cells. Other vaccines are currently only targeting the systemic immune system, but we know from our research that COVID -19 is a mucosal virus, therefore all vaccine developers should also be looking for a vaccine that targets both mucosal and systemic immunity. This is what OraPro- COVID-19 delivers in a single capsule,” the company’s chairman Wayne Channon explained.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
